Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed

Despite strong Q1 sales for Eli Lilly's Zepbound ($2.3B) and Novo Nordisk's Wegovy ($1.9B), access to these high-demand GLP-1 obesity drugs remains challenging due to high out-of-pocket costs (around $500/month without insurance) and inconsistent insurance coverage, notably from state and federal programs. While some large employers are expanding coverage, pharmacy benefit managers (PBMs) are making cost-driven formulary decisions, and the contentious market for compounded versions persists. However, anticipated oral formulations and growing international competition are expected to drive further price reductions, potentially broadening future access.

Analysis

The GLP-1 obesity drug market continues to demonstrate strong commercial momentum, with Eli Lilly's Zepbound generating $2.3 billion and Novo Nordisk's Wegovy $1.9 billion in U.S. first-quarter sales. However, significant access and pricing headwinds persist, constraining the total addressable market. High out-of-pocket costs, averaging $500 per month for the uninsured, and inconsistent insurance coverage, particularly the exclusion from most Medicaid and Medicare programs, remain critical barriers. The competitive dynamics are intensifying, with pharmacy benefit managers (PBMs) like CVS Health exerting considerable influence by making formulary decisions, such as dropping Zepbound in favor of Wegovy, which directly impacts market share. Furthermore, the market faces disruption from lower-cost compounded versions, a contentious issue creating legal and reputational risks for firms like Hims & Hers Health, as evidenced by litigation from Eli Lilly and Novo Nordisk's terminated partnership. Future price erosion is a key factor to watch, with the potential introduction of oral formulations in the next year and growing competition from international pharmacies expected to exert downward pressure on current prices.

Key Decisions for Investors

• Investors should closely monitor pharmacy benefit manager (PBM) formulary decisions, as CVS favoring Wegovy over Zepbound indicates that these choices are becoming a critical determinant of market share between Novo Nordisk and Eli Lilly.
• Consider the potential for long-term margin compression for both LLY and NVO, as the anticipated market entry of oral GLP-1 versions and rising international price competition will likely pressure the pricing of existing injectable drugs.
• The business model of Hims & Hers Health faces significant legal and regulatory headwinds from litigation by major drugmakers and the official end of the FDA-recognized drug shortage, posing a risk to its compounded drug revenue stream.
• The pace of insurance coverage expansion, especially potential inclusion in federal programs like Medicare, remains the most significant catalyst for unlocking the full market potential for these obesity treatments.